Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs TG Therapeutics Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Global X NASDAQ 100 Covered Call ETF and TG Therapeutics Inc are close in size by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and TG Therapeutics Inc for 16 Days on average.
| QYLD | TGTX | |
|---|---|---|
Market Cap | $8.49B | $8.16B |
Volume | 2,913,938 | 1,735,121 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.68 | $59.06 |
52-Week Low | $16.70 | $26.94 |
Typical Hold Time | 51 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.685 with minimal daily movement (+0.03%), showing technical bullish signals from moving averages but bearish oscillator readings including overbought RSI levels. The ETF maintains consistent monthly dividend distributions of $0.18 per share, though recent news highlights concerns about declining option premiums and long-term capital erosion despite the attractive yield.
The outlook remains cautious as covered call strategies limit upside participation during market rallies. While providing reliable income, QYLD faces structural headwinds including capped growth potential and potential tax reclassification of distributions. Investors should weigh the trade-off between high current yield and long-term total return potential.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
